MammaPrint is a genomic test that analyzes the activity of a group of genes in early-stage breast cancer. This test can help determine the risk of cancer recurrence and guide treatment decisions. It categorizes patients into high-risk or low-risk groups based on the likelihood of cancer returning within 10 years after diagnosis.
